Tooth Extraction
Conditions
Interventions
This is a prospective, randomized, double-blind, split-mouth clinical trial. A total of 20 participants who meet the eligibility criteria will be included in the study. Each participant will undergo t
Sponsors
Faculdade de Odontologia de Piracicaba – Universidade Estadual de Campinas
Universidade Estadual de Campinas
Eligibility
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 30 years; ASA I (American Society of Anesthesiologists physical status classification I); Presence of mandibular third molars in similar positions; Not using any medication routinely or within the week prior to the study; No known allergy to the drugs used in the study; Surgical site without current signs or symptoms of infection.
Exclusion criteria
Exclusion criteria: Patients with a history of pregnancy or lactation; History of gastrointestinal bleeding or peptic ulcer; Allergy to aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs); Patients under continuous use of psychoactive drugs, analgesics, or steroidal and nonsteroidal anti-inflammatory agents; Smokers; Presence of postoperative infection signs or symptoms.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1 A significant difference in postoperative pain intensity between pharmacological regimens is expected, assessed using the Visual Analog Scale (VAS), based on a minimum difference of 2 points on a 0–10 scale at 2, 6, 12, 24, 48, and 72 hours after surgery.;Observed outcome 1 A statistically significant difference in postoperative pain intensity between pharmacological regimens was observed only at 2 hours after surgery, with higher pain scores reported in the dexamethasone group compared to the nimesulide group (p = 0.0222), assessed using the Visual Analog Scale (VAS). No significant differences were observed at the other evaluated time points.;Expected outcome 2 A significant difference in postoperative facial swelling between pharmacological regimens is expected, assessed through standardized linear facial measurements, based on a minimum difference of 5% at 3 and 7 days after surgery.;Observed outcome 2 No statistically significant differences were observed between pharmacological regimens in postoperative facial swelling, measured using standardized linear facial measurements, at 3 and 7 days after surgery (p = 0.6938).;Expected outcome 3 A significant difference in postoperative limitation of mouth opening between pharmacological regimens is expected, assessed by measuring maximum interincisal distance with a millimeter ruler, based on a minimum difference of 5 mm at 3 and 7 days after surgery.;Observed outcome 3 No statistically significant differences were observed between pharmacological regimens regarding postoperative limitation of mouth opening, assessed by maximum interincisal distance, at 3 and 7 days after surgery (p = 0.7484). | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 4 A significant difference in salivary prostaglandin E2 (PGE2) levels between pharmacological regimens is expected, assessed using the ELISA method, based on percentage variation in PGE2 levels at the preoperative period, immediate postoperative period, and at 3 and 7 days after surgery.;Observed outcome 4 No statistically significant differences were observed in salivary prostaglandin E2 (PGE2) levels between pharmacological regimens at any evaluated time point (p > 0.05). A significant increase in PGE2 levels was observed in the nimesulide group at 7 days compared to 3 days after surgery (p = 0.0279), without associated clinical relevance. | — |
Countries
Brazil
Contacts
Public ContactRenato Ribeiro
Faculdade de Odontologia de Piracicaba – Universidade Estadual de Campinas
Outcome results
None listed